Prashanthi Vemuri1, Heather J. Wiste1, Stephen D. Weigand1, Leslie M. Shaw2, John Q. Trojanowski2, Michael Weiner3, Ronald C. Petersen1, Clifford R. Jack Jr1
1Mayo Clinic and Foundation, Rochester, MN, USA; 2University of Pennsylvania School of Medicine; 3University of California at San Francisco
MRI and CSF biomarkers that closely reflect the underlying biology add value to clinical assessment as well as to the understanding of mechanisms underlying Alzheimers disease (AD). Our objective was to assess the correlations of both MRI and cerebro spinal fluid (CSF) biomarkers with clinical diagnosis and cognitive performance at baseline, and also assess the ability of these disease indicators to predict future cognitive decline. We examined these questions using data from the Alzheimers disease Neuroimaging Initiative (ADNI) study which consists of a large database of cognitively normal (CN), amnestic mild cognitive impairment (aMCI) and AD with both CSF and MRI.